TR200909787A2 - Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid. - Google Patents

Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid.

Info

Publication number
TR200909787A2
TR200909787A2 TR2009/09787A TR200909787A TR200909787A2 TR 200909787 A2 TR200909787 A2 TR 200909787A2 TR 2009/09787 A TR2009/09787 A TR 2009/09787A TR 200909787 A TR200909787 A TR 200909787A TR 200909787 A2 TR200909787 A2 TR 200909787A2
Authority
TR
Turkey
Prior art keywords
clavulanic acid
generation cephalosporin
pharmaceutical formulations
formulations containing
salts
Prior art date
Application number
TR2009/09787A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2009/09787A priority Critical patent/TR200909787A2/en
Priority to EP10798856A priority patent/EP2515905A1/en
Priority to PCT/TR2010/000240 priority patent/WO2011078820A1/en
Publication of TR200909787A2 publication Critical patent/TR200909787A2/en
Priority to US13/532,120 priority patent/US8614315B2/en
Priority to US14/089,355 priority patent/US20140079647A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Bu buluş dirençli bakterilerin neden olduğu enfeksiyonların tedavisi için sefdinir, sefiksim ve sefpodoksim proksetil'i içeren grup içerisinden seçilen üçüncü kuşak bir sefalosporin ve klavulanik asit ve/ veya bunların farmasötik kabul edilebilir tuzları, hidratları, enantiomerleri, rasematları, organik tuzları, inorganik tuzları, esterleri, polimorflan, kristal formları ve amorf formları ve/veya bunlara ait kombinasyonları içeren farmasötik bileşimlere ilişkindir.The present invention is a third generation cephalosporin selected from the group consisting of cefdinir, cefixime and cefpodoxime proxetil for the treatment of infections caused by resistant bacteria and clavulanic acid and / or their pharmaceutically acceptable salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters. relates to pharmaceutical compositions containing polymorphs, crystal forms and amorphous forms and / or combinations thereof.

TR2009/09787A 2009-12-25 2009-12-25 Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid. TR200909787A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
TR2009/09787A TR200909787A2 (en) 2009-12-25 2009-12-25 Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid.
EP10798856A EP2515905A1 (en) 2009-12-25 2010-12-03 Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid
PCT/TR2010/000240 WO2011078820A1 (en) 2009-12-25 2010-12-03 Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid
US13/532,120 US8614315B2 (en) 2009-12-25 2012-06-25 Cefdinir and cefixime formulations and uses thereof
US14/089,355 US20140079647A1 (en) 2009-12-25 2013-11-25 Cefdinir and cefixime formulations and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2009/09787A TR200909787A2 (en) 2009-12-25 2009-12-25 Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid.

Publications (1)

Publication Number Publication Date
TR200909787A2 true TR200909787A2 (en) 2011-07-21

Family

ID=43568755

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2009/09787A TR200909787A2 (en) 2009-12-25 2009-12-25 Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid.

Country Status (3)

Country Link
EP (1) EP2515905A1 (en)
TR (1) TR200909787A2 (en)
WO (1) WO2011078820A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201000686A1 (en) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Water-soluble cefdinir and clavulanic acid formulations for the treatment of bacterial infections.
TR201010212A2 (en) * 2010-12-08 2012-06-21 Bi̇lgi̇ç Mahmut Solid oral dosage form containing cefdinir.
KR20190039137A (en) 2016-07-14 2019-04-10 아카오젠, 인코포레이티드 Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508977A (en) 1974-04-20 1978-04-26 Beecham Group Ltd Beta-lactam antibiotic from streptomyces clavuligerus
JO984B1 (en) 1977-10-11 1979-12-01 بيتشام غروب ليمتد K-clavulanate/tri hydrate formulations
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
CZ299595B6 (en) 1995-09-07 2008-09-17 Smithkline Beecham Plc Pharmaceutical formulation and medicament for empiric treatment of infections
PE20010053A1 (en) 1999-04-13 2001-03-10 Beecham Pharm Pte Ltd AMOXICILLIN AND POTASSIUM CLAVULANATE FORMULATION
FR2881755B1 (en) * 2005-02-10 2012-11-30 Biomerieux Sa MEDIA FOR THE SPECIFIC DETECTION OF RESISTANT MICROORGANISMS
WO2007086012A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation of cefpodoxime, clavulanic acid and linezolid
CN101129381B (en) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 Antibiotic compound containing beta-lactam antibiotic and ion chelating agent
CN101744827B (en) * 2008-12-15 2012-05-30 天津中敖生物科技有限公司 Medicinal composition for killing chicken colibacillosis and preparation method and use thereof

Also Published As

Publication number Publication date
EP2515905A1 (en) 2012-10-31
WO2011078820A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
UY33044A (en) DERIVATIVES OF CARBAMOIL-METHYL-AMINO-ACETIC ACID REPLACED AS NOVEDOUS NEP INHIBITORS
PH12014502224A1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
HK1165954A1 (en) Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
MX2011007737A (en) Hydroxy-methyl isoxazole derivatives as gaba a modulators.
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
ECSP11010980A (en) FUSIONED SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
MX2011011484A (en) Isoxazole-pyridine derivatives as gaba modulators.
UY33731A (en) ? AMINO-PHENYL-PENTANOIC ACID DERIVATIVES REPLACED AS NEP INHIBITORS?
PE20141204A1 (en) NOVEL COMPOUNDS AS INHIBITORS OF DIACILGLICEROL ACILTRANSFERASE
EA201391158A8 (en) DIAMINIC PHENOTIAZINE SALTS AND THEIR APPLICATION
WO2011093826A3 (en) Effervescent formulations comprising cefaclor and clavulanic acid as active agents
MX2011007772A (en) Isoxazole / o-pyridine derivatives with ethyl and ethenyl linker.
MX2013000295A (en) Process of preparing a thrombin specific inhibitor.
MX2011007952A (en) Novel tricyanoborates.
IN2012DN02502A (en)
EA201690072A1 (en) COMPOSITION CONTAINING HYPOLIPIDEMIC MEANS
PE20150021A1 (en) 5-AMINO [1,4] THIAZINES AS BACE1 INHIBITORS
MX2016002718A (en) KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS.
WO2010132670A3 (en) Pentacycline compounds
TR200909787A2 (en) Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid.
MX2012007836A (en) Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring.
MX2012007833A (en) Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring.
MX2013002462A (en) Heterocyclic compounds as dgat1 inhibitors.
TR201000686A1 (en) Water-soluble cefdinir and clavulanic acid formulations for the treatment of bacterial infections.
MX2012013589A (en) 2 -amino- pyrimidine derivatives useful as inhibitors of jnk.